Literature DB >> 29052260

Increased survival rates in gastric cancer, with a narrowing gender gap and widening socioeconomic status gap: A period analysis from 1984 to 2013.

Fengze Sun1, Huanhuan Sun1, Xiangqiong Mo2, Jianjun Tang3, Yifeng Liao1, Shuncong Wang1, Yonghui Su2, Haiqing Ma1.   

Abstract

BACKGROUND AND AIM: Gastric cancer (GC) has the fifth highest incidence rate of all cancers and has a poor prognosis. However, no recent large-scale and long-term studies have evaluated the incidence and survival rates of individuals with GC.
METHODS: In order to explore the change of GC incidence and survival rates by age, gender, race, and socioeconomic status (SES), incidence data and survival status of patients with GC between 1984 and 2013 were abstracted from the Surveillance, Epidemiology, and End Results database. Totally, 87 242 cases of GC were exported and were analyzed.
RESULTS: During these three decades, the incidence of GC was 7.4, 6.8, and 5.5 per 100 000 individuals in each decade. The 1-year relative survival rates (RSRs) improved from 42.4% to 44.3% to 49.0% (P < 0.0001), with a larger increase seen in the third decade. However, the long-term survival rates remained low (from 17.8% to 20.3% to 22.9% for the 5-year RSRs, P < 0.0001; from 14.1% to 16.4% to 18.6% for the 10-year RSRs, P < 0.0001).
CONCLUSION: Our analysis demonstrated the decreased incidence and increased survival rate of GC. In addition, lower SES was associated with lower survival rates. It is notable that others (primarily for Asians) had the highest incidence rate but had better outcomes than Whites and Blacks.
© 2017 Journal of Gastroenterology and Hepatology Foundation and John Wiley & Sons Australia, Ltd.

Entities:  

Keywords:  gastric cancer; gastric cancer incidence; race; socioeconomic status; survival rate

Mesh:

Year:  2018        PMID: 29052260     DOI: 10.1111/jgh.14024

Source DB:  PubMed          Journal:  J Gastroenterol Hepatol        ISSN: 0815-9319            Impact factor:   4.029


  11 in total

1.  eIF4EBP3 was downregulated by methylation and acted as a tumor suppressor by targeting eIF4E/β-catenin in gastric cancer.

Authors:  Shuting Zhai; Shuang Lin; Zhongjie Lin; Junjie Xu; Tong Ji; Ke Chen; Ke Wu; Hui Liu; Hanning Ying; Weiqiang Fei; Jin Wang; Guoxiang Fu; Yifan Wang; Xiaotong Hu; Xiujun Cai
Journal:  Gastric Cancer       Date:  2019-12-18       Impact factor: 7.370

2.  Diagnostic value of serum levels of galanin and obestatin in patients with gastric cancer.

Authors:  Furkan Ali Uygur; Esra Dişçi; Rıfat Peksöz; Nurinnisa Öztürk; Mehmet İlhan Yildirgan; Yavuz Albayrak
Journal:  Rev Assoc Med Bras (1992)       Date:  2022-07       Impact factor: 1.712

3.  Associations of Education Level With Survival Outcomes and Treatment Receipt in Patients With Gastric Adenocarcinoma.

Authors:  Jiaxuan Xu; Shuhui Du; Xiaoqing Dong
Journal:  Front Public Health       Date:  2022-06-09

4.  CCL21 activation of the MALAT1/SRSF1/mTOR axis underpins the development of gastric carcinoma.

Authors:  Qianmei Fu; Xiaohong Tan; Huaming Tang; Jijiang Liu
Journal:  J Transl Med       Date:  2021-05-17       Impact factor: 5.531

5.  Dysregulation of NCAPG, KNL1, miR-148a-3p, miR-193b-3p, and miR-1179 may contribute to the progression of gastric cancer.

Authors:  Bin Song; Juan Du; De-Feng Song; Ji-Chen Ren; Ye Feng
Journal:  Biol Res       Date:  2018-11-03       Impact factor: 5.612

6.  A Systems Pharmacology Approach for Identifying the Multiple Mechanisms of Action of the Wei Pi Xiao Decoction for the Treatment of Gastric Precancerous Lesions.

Authors:  Liangjun Yang; Wei Liu; Zhipeng Hu; Maoyi Yang; Jiali Li; Xiangzhen Fan; Huafeng Pan
Journal:  Evid Based Complement Alternat Med       Date:  2019-02-03       Impact factor: 2.629

7.  A Novel Inflammatory-Nutritional Prognostic Scoring System for Stage III Gastric Cancer Patients With Radical Gastrectomy Followed by Adjuvant Chemotherapy.

Authors:  Nan Wang; Wenqi Xi; Sheng Lu; Jinling Jiang; Chao Wang; Zhenglun Zhu; Chao Yan; Jing Liu; Jun Zhang
Journal:  Front Oncol       Date:  2021-06-14       Impact factor: 6.244

Review 8.  The evolving immunotherapeutic landscape in advanced oesophagogastric cancer.

Authors:  Michael Flynn; Kate Young; David Cunningham; Naureen Starling
Journal:  Ther Adv Med Oncol       Date:  2018-07-11       Impact factor: 8.168

9.  High expression of ghrelin and obestatin prepropeptide in tumor tissues predicted adverse overall survival in gastric carcinoma patients.

Authors:  Xiandan Wu; Yongning Wu; Binhua Ye; Fubin Wu; Peien Wang
Journal:  Medicine (Baltimore)       Date:  2020-06-26       Impact factor: 1.817

10.  Epidemiological Trends of Head and Neck Cancer: A Population-Based Study.

Authors:  Kangwen Guo; Weiliang Xiao; Xinggui Chen; Zhenying Zhao; Yuanxiong Lin; Ge Chen
Journal:  Biomed Res Int       Date:  2021-07-14       Impact factor: 3.411

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.